| Previous Close | 2.87 |
| Open | 2.70 |
| Bid | 2.24 x 200 |
| Ask | 2.45 x 2000 |
| Day's Range | 2.29 - 2.73 |
| 52 Week Range | 0.78 - 5.59 |
| Volume | 5,200,021 |
| Avg. Volume | 2,470,257 |
| Market Cap | 30.67M |
| Beta | N/A |
| PE Ratio (TTM) | -1.01 |
| EPS (TTM) | -2.28 |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.50 |
- SmarterAnalyst•12 hours ago
AEterna Zentaris Inc. (USA) (AEZS) CEO’s Departure Raises Questions
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are tumbling nearly 7% in Monday's trading session, following the news that CEO David Dodd is stepping down and will be succeed by Michael Ward. Most recently, Ward served as Chief Compliance & Legal Officer and Corporate Secretary for Sagent Pharmaceuticals and led its sale to Nichi-Iko Pharmaceutical for $736 million. If David Dodd turned around AEZS, why is he out?
- Business Wire•4 days ago
Aeterna Zentaris Forms Strategic Review Committee and Appoints Michael Ward as CEO
Aeterna Zentaris Inc. , announced today that it has formed a special committee of independent directors to consider and evaluate various strategic and financing alternatives available to the Company to maximize shareholder value, including continuing to execute on its existing business plan and/or considering and recommending changes to the Company’s management and governance.
- Accesswire•5 days ago
Today's Research Reports on Stocks to Watch: Vertex Pharmaceuticals and Aeterna Zentaris
NEW YORK, NY / ACCESSWIRE / July 20, 2017 / Both Vertex Pharmaceuticals and Aeterna Zentaris saw their share prices pop on Wednesday and received price target increases from Maxim. Vertex stormed ahead ...
